NYSE: GSK

Explore the latest insights on NYSE: GSK and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of NYSE: GSK’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

European Commission Approves Merck's KEYTRUDA Plus Padcev for Resectable Muscle-Invasive Bladder Cancer – First and Only PD-1 Inhibitor–ADC Regimen for MIBC in the EU
CompanyDrug

European Commission Approves Merck’s KEYTRUDA Plus Padcev for Resectable Muscle-Invasive Bladder Cancer – First and Only PD-1 Inhibitor–ADC Regimen for MIBC in the EU

Merck & Co., Inc. (MSD; NYSE: MRK) announced that the European Commission (EC) has approved KEYTRUDA (pembrolizumab) in combination with Padcev (enfortumab vedotin‑ejfv) as neoadjuvant treatment, continued after radical cystectomy…

Siemens Healthineers and NVIDIA Partner to Develop Next-Generation Adaptive Radiotherapy Technology – Combining Agentic and Robotic Intelligence With Accelerated Computing

Siemens Healthineers and NVIDIA Partner to Develop Next-Generation Adaptive Radiotherapy Technology – Combining Agentic and Robotic Intelligence With Accelerated Computing

Reju Therapeutics Completes Oversubscribed Series A Financing of Hundreds of Millions of RMB – China's First Senotherapeutics Biotech Backed by Top-Tier Investors

Reju Therapeutics Completes Oversubscribed Series A Financing of Hundreds of Millions of RMB – China’s First Senotherapeutics Biotech Backed by Top-Tier Investors

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Da Ren Tang Sells Stake in Tianjin Shike to Haleon for RMB 1.623 Billion
CompanyDeals

Da Ren Tang Sells Stake in Tianjin Shike to Haleon for RMB 1.623 Billion

ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform
CompanyDeals

ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform

GSK's Blujepa Approved by FDA for Uncomplicated Urinary Tract Infections
CompanyDrug

GSK’s Blujepa Approved by FDA for Uncomplicated Urinary Tract Infections

GSK's Nucala Accepted for EMA Review for COPD Treatment
CompanyDrug

GSK’s Nucala Accepted for EMA Review for COPD Treatment

GSK's Depemokimab Accepted for FDA Review as Ultra-Long-Acting Biologic
CompanyDrug

GSK’s Depemokimab Accepted for FDA Review as Ultra-Long-Acting Biologic

GSK's Nucala Receives NMPA Review for COPD Treatment
CompanyDrug

GSK’s Nucala Receives NMPA Review for COPD Treatment

GSK Reports 7% Full-Year Sales Growth in 2024, Driven by Specialty Medicines
Company

GSK Reports 7% Full-Year Sales Growth in 2024, Driven by Specialty Medicines

GSK's Jemperli Approved for First-Line Endometrial Cancer Treatment in EU
CompanyDrug

GSK’s Jemperli Approved for First-Line Endometrial Cancer Treatment in EU

Show More